The anti-doping case that began with a routine post-race declaration at the Cherry Blossom 10 Miler has ended with one of the heaviest sanctions in recent road-running memory.
USADA confirmed that Ethiopian distance runner Adane Anmaw Mengesha has accepted a five-year ban for multiple anti-doping rule violations, including the use of prohibited intravenous infusions and tampering with the Therapeutic Use Exemption (TUE) process.
Mengesha, 22, finished second at the Cherry Blossom 10 Miler in Washington D.C. on April 4, 2025, a USA Track & Field-sanctioned event. During sample collection after the race, she declared that she had used an amino acid solution delivered via intravenous infusion.
That admission opened the door.
USADA’s investigation uncovered that Mengesha had received multiple IV infusions in excess of 100 mL per 12-hour period between March 26 and March 30, 2025. The infusions, prescribed by a doctor to treat a medical condition, did not involve any prohibited substances. The problem lay elsewhere: the volume and the context.
Under the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List, IV infusions or injections totaling more than 100 mL per 12-hour period are classified as Specified Methods and are banned at all times unless they fall under narrow exceptions such as hospital treatment, surgical procedures, or clinical diagnostic investigations. Mengesha’s infusions did not meet any of those exemptions.
The rule is blunt. The volume alone can constitute a violation, regardless of what goes into the drip.
The case then took a more serious turn.
Working in coordination with the Ethiopian Anti-Doping Authority (ETH-ADA), USADA determined that Mengesha committed a tampering violation while trying to legitimize the treatment retroactively. When applying to ETH-ADA for a TUE, she submitted falsified documents that claimed the infusions had been administered at a hospital in Addis Ababa.
As an Ethiopian athlete, Mengesha was required to file her TUE application with ETH-ADA. By presenting falsified paperwork, she not only failed to secure a valid exemption but also deepened the offense. The attempted cover-up dragged out the investigation and hardened the eventual sanction.
Under Article 10.8.1 of the Code, athletes facing a sanction of four years or more can receive a one-year reduction if they admit the violation and accept the proposed sanction within 20 days of being notified of the charge. Mengesha met those conditions, trimming her punishment from an initially asserted six-year period of ineligibility down to five.
Her ban is backdated to November 5, 2025, the day she was provisionally suspended. All results from April 4, 2025 onward are disqualified, including her second-place finish at the Cherry Blossom 10 Miler, with forfeiture of any medals, points, and prize money.
The case underscores a familiar tension in elite sport: athletes and their support teams navigating complex medical needs within a rigid anti-doping framework. The rules around infusions are clear, the volume limits strict, and the paperwork unforgiving.
USADA, for its part, continues to lean heavily on education and access to information. The agency offers detailed guidance on testing procedures, prohibited methods and substances, athlete Whereabouts requirements, TUE applications, and the risks tied to supplements and performance-enhancing or recreational drugs. It runs Global Drug Reference Online, maintains a drug reference hotline, and pushes out handbooks, nutrition and supplement guides, and regular alerts to athletes and support personnel.
It also keeps multiple reporting channels open for tips on doping abuse, from online forms to text, email, phone, and mail, as it polices the U.S. Olympic and Paralympic Movement and tries to protect athletes who compete clean.
For Mengesha, though, the education arrives too late. At 22, she now faces the stark reality of five years off the track at a time when most distance runners are only beginning to hit their stride.
